Serotonin: It's Possible to Have Too Much of a Good Thing
J Clin Psychiatry 1997;58:520-521
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Serotonin has been at the heart of innovation in psychopharmacology for the past decade. Serotonin selective reuptake inhibitors (SSRIs) in particular have led the way, but many other agents also act on serotonin, in one fashion or another. These include other antidepressants, as well as novel atypical antipsychotics, various antiemetics, modern migraine therapies, and certain drugs of abuse. Also included is the appetite suppressant fenfluramine, both in its d,l form (Pondimin) and in its pure d form (Redux).